Fig 1: TMEM107 inhibits invasion and EMT of NSCLC cells. (a) TMEM107 and Gli1 levels in HBE cells and six NSCLC cell lines determined by western blot analysis. (b) Densitometric quantification of western blot results. (c) Western blot analysis of transfection efficiency and (d) knockdown efficiency of TMEM107 in A549 and H460 cells (e, f) Densitometric quantification of western blot results from c and d, respectively. (g, h) q‐RT‐PCR assay for transfection efficiency. (i) Transwell assay to assess cell invasion after TMEM107 knockdown and overexpression. (j) The histogram of the number of cells invaded. (k) Expression of invasion‐related proteins after TMEM107 downregulation and overexpression. (l) Densitometric quantification of western blot results from (k). (m) Expression of EMT‐related proteins after TMEM107 upregulation and downregulation. (n) Densitometric quantification of western blot results from (m) (*P < 0.05). (b) () TMEM107, () Gli1; (e) () p‐NC, () p‐107; (f) () Si‐NC, () Si‐107; (g) () p‐NC, () p‐107; (h) () Si‐NC, () Si‐107; (j) () si‐NC, () si‐TMEM107; () p‐NC, () p‐TMEM107
Fig 2: Expression of TMEM107 in lung cancer analyzed by Oncomine datasets. (a) The gene copies of TMEM107 were significantly downregulated in many kinds of cancers. (b,c) The gene copies of TMEM107 were downregulated in LUAC and LUSC in Weiss and TCGA lung statistics. (d) The mRNA expression of TMEM107 was negatively correlated with tumor grade and N stage in lung cancer.
Fig 3: Downregulation of TMEM107 promotes EMT and migration in NSCLC by activating the Hedgehog signaling pathway. (a) Expression of Gli1 after TMEM107 upregulation and downregulation in A549 and HCC460 cell lines. (b) Densitometric quantification of western blot results from (a). (c) Western blot analysis of GLI1 in A549 cells incubated with GANT61 (0–20 μM) for 48 hours using DMSO as control. (d) Inhibition efficiency curve of GANT61 on Gli1 based on (c). (e) Transwell assay to assess cell invasion after Hedgehog inhibition with GANT61 in A549 and H460 cells transfected with si‐TMEM107. (f) The histogram of the number of cells invaded. (g) Effects of GANT61 treatment on the expression of EMT‐ and invasion‐related proteins in A549 and H460 cells transfected with si‐TMEM107. (h) Densitometric quantification of western blot results from (g) (*P < 0.05). (f) ) si‐NC, () si‐TMEM107; ) si‐107+GANT61; (h) ) si‐NC, () si‐TMEM107; ) si‐107+GANT61
Fig 4: TMEM107 expression is lower in NSCLC tissues and correlates with poor prognosis. (a) TMEM107 protein levels in 12 pairs of NSCLC and adjacent tissues. (b, c) Densitometric quantification of western blot results. *P < 0.05, **P < 0.01, ****P < 0.0001. (d) TMEM107 expression analyzed by immunohistochemistry in (a) healthy bronchial epithelial cells and (b) alveolar (c) well‐differentiated squamous cell carcinoma and (d) adenocarcinoma, and (e) poorly differentiated squamous cell carcinoma and (f) adenocarcinoma. (400×). (e) The prognostic value of TMEM107 tested with the Kaplan‐Meier plotter. Hazard ratio (HR), 95% confidence interval (CI) and P‐value are indicated. (f, g) The prognostic value of TMEM107 via the SurvExpress. (f) The survival analysis between low risk (green) and high risk (red) groups. (g) TMEM107 expression is lower in the high risk group than in the low risk group. (b) () ca, () p; (c) () ca, () p; (e) () low, () high; (f) () 54, +:31, CI = 55.5, () 54, +:19, CI = 47.1; (g) () 2‐Low Risk, () 2‐High Risk
Supplier Page from Abcam for Anti-TMEM107 antibody - N-terminal